J Korean Med Assoc.  2010 Feb;53(2):135-141.

Prevention of Prostate Cancer

• Chung JI

Abstract

Prostate cancer can be prevented more easily than other types of cancers, thanks to the following reasons: The presence of precursor lesions, longer doulbling time of cancerous cells, high incidence and prevalence, and susceptibility to chemo-preventive agents such as 5 alpha reductase inhibitor (5ARI). The following risk factors may increase the incidence of prostate cancer: age (older than 50), family history of prostate cancer, race (African-American), hormones (testosterone, dehydrotestosterone), and diet high in dairy foods and calcium. The following protective factors may decrease the risk of prostate cancer: Lycopene, Soy, Green tea, Vit. D, and taking Finasteride or Dutasteride. The following have not been proven to prevent prostate cancer: Selenium, vitamin E, retinoid, and multivitamins. However, their effectiveness is still under investigation. Avoiding risk factors such as smoking, being overweight and lack of exercise may help prevent cancers. Increasing protective factors such as quitting smoking, eating a healthy diet and exercising may also help prevent cancers. Some clinical studies are conducted on polyphenon E for high grade PIN, Vitamin D, fish oil, green tea, and aspirin for prostate cancer prevention. Prostate cancer is an attractive and appropriate target for cancer prevention because of its incidence, prevalence and disease-related mortality. In addition to changing life style with healthy food and reducing dairy and calcium intake, taking certain drugs (5ARI) may prevent cancer development.

Keyword

Prostate cancer; Prevention

MeSH Terms

Aspirin
Azasteroids
Calcium
Carotenoids
Catechin
Cholestenone 5 alpha-Reductase
Continental Population Groups
Diet
Dutasteride
Eating
Finasteride
Humans
Incidence
Life Style
Overweight
Prevalence
Prostate
Prostatic Neoplasms
Risk Factors
Selenium
Smoke
Smoking
Tea
Vitamin D
Vitamin E
Vitamins
Aspirin
Azasteroids
Calcium
Carotenoids
Catechin
Cholestenone 5 alpha-Reductase
Finasteride
Selenium
Smoke
Tea
Vitamin D
Vitamin E
Vitamins

Reference

1. Armstrong B, Doll R. Environmmmental factors and cancer incidence and mortality in different countries with special reference to dietary practices. Int J Cancer. 1975. 15:617–631.

2. Bequet CR, Horm JW, Gibbs T, Greenwald P. Socioeconomic factors and cancer incidence among black and whites. J Natl Cancer Inst. 1991. 83:551–557.

3. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implicatons for prostatic carcinogenesis. Am J Pathol. 1999. 155:1985–1992.

4. Febbo PG, Kantoff PW, Platz EA, Casey D, Batter S, Giovannucci E, Hennekens CH, Stampfer MJ. The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer. Cancer Res. 1999. 1:5878–5881.

5. Carter HB, Piantadosi S, Issacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol. 1990. 143:742–746.

6. Brawley OW, Barnes S, Parnes H. The future of prostate cancer prevention. Ann NY Acad Sci. 2001. 952:145–152.

7. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the develop-ment of postate cancer. N England J Med. 2003. 349:215–224.

8. Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride:US/European Perspective. Eur Urol. 2003. 44:650–655.

9. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Tindall D, Breed S, Somerville M, Rittmaster R. REDUCE Study Group. Chemoprevention of prostate cancer (REDUCE) trial. J Urol. 2004. 172:1314–1317.

10. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongro A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR. Nutritional Prevention of Caccer Study Group. Effects of selenium supplementation for cencer prevention in patients with carcinoma of the skin. A rando-mized controlled trial. JAMA. 1996. 25:1957–1963.

11. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Mäenpää H, Teerenhovi L, Koss L, Virolainen M, Edwards BK. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst. 1998. 90:440–446.

12. Klein EA. Selenium-eqidemiology and basic science. J Urol. 2004. 171:S50–S53.

13. Duffield-Lillico Aj, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR, Clark LC. Nutritional Prevention of Cancer Study Group. Se supplementation, baseline plasma Se status, and incidence of prostate cancer: An analysis of the complet treatment period of the nutritional prevention of cancer study group. BJU Int. 2003. 91:608–612.

14. Ni J, Chen M, Zhang Y, Li R, Huang J, Yeh S. Vitamin E succinate inhibits human prostate cancer cell growth via modulating cell cycle regulatory machinery. Biochem Biophys Res Commun. 2003. 300:357–363.

15. Thompson TA, Wilding G. Androgen antagonist activity by the antioxidant moiety of vitamin E, 2,2,5,7,8-pentamethyl-6-chromanol in human prostate carcinoma cells. Mol Cancer Ther. 2003. 2:797–803.

16. Albanes D, Heinonen OP, Huttunen JK, Taylor PR, Virtamo J, Edwards BK, Haapakoski J, Rautalahti M, Hartman AM, Palmgren J. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr. 1995. 62:S6. 1427S–1430S.

17. Pak RW, Lanteri VJ, Scheuch JR, Sawczuk IS. Review of Vitamine E and Selenium in the prevenrtion of prostate cancer: implications of the selenium and vitaman E chemopreventive trial. Integr Cancer Ther. 2002. 1:338–344.

18. Lippman SM, Goodman PJ, Klein EA, Parnes HL, Thompson IM Jr, Kristal AR, Santella RM, Probstfield JL, Moinpour CM, Albanes D, Taylor PR, Minasian LM, Hoque A, Thomas SM, Crowley JJ, Gaziano JM, Stanford JL, Cook ED, Fleshner NE, Lieber MM, Walther PJ, Khuri FR, Karp DD, Schwartz GG, Ford LG, Coltman CA Jr. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst. 2005. 97:94–102.

19. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009. 301:39–51. Epub 2008 Dec 9.

20. Schwartz GC, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer [Hypothesis]. Anticancer Res. 1990. 10:1307–1311.

21. Guyton KZ, Kensler TW, Psosner GH. Vitamin D and Vitamin D analogs as cancer chemopreventive agents. Natl Rev. 2003. 61:227–238.

22. Reichman ME, Hayes RB, Zeiegler RG, Schatzkin A, Taylor PR, Kahle LL, Fraumeni JF JR. Serum vitamin A and subsequent development of prostate cancer in the first national health and nurtition examination survey epidemiologic follow up study. Cancer Res. 1990. 50:2311–2315.

23. Hussain T, Gupta S, Mukhtar H. Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett. 2003. 05. 10. 191:125–135.

24. Cohen LA, Zhao Z, Pittman B, Scimeca J. Effect of soy protein isolate and conjugated linoleic acid on the growth of Dunning R-3327-AT-1 rat prostate tumors. Prostate. 2003. 54:169–180.

25. Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hämäläinen E, Hasegawa T, Okada H. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr. 1991. 54:1093–1100.

26. Giovannucci E. Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature. J Natl Cancer Inst. 1999. 91:317–331.

27. Adhami VM, Ahmad N, Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr. 2003. 133:S 7. 2417S–2424S.

28. Hultdin J, Van Guelpen B, Bergh A, Hallmans G, Stattin P. Plasma folate, vitamin B12, and homocysteine and prostate cancer risk: a prospective study. Int J Cancer. 2005. 113:819–824.

29. Rodriguez C, McCullough ML, Mondul AM, Jacobs EJ, Fakhrabadi-Shokoohi D, Giovannucci EL, Thun MJ, Calle EE. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol Biomarkers Prev. 2003. 12:597–603.

30. Ahn J, Albanes D, Peters U, Schatzkin A, Lim U, Freedman M, Chatterjee N, Andriole GL, Leitzmann MF, Hayes RB. Prostate, Lung, Colorectal, and Ovarian Trial Project Team. Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2007. 16:2623–2630.

31. Johansson M, Appleby PN, Allen NE, Travis RC, Roddam AW, Egevad L, Jenab M, Rinaldi S, Kiemeney LA, Bueno-de-Mesquita HB, Vollset SE, Ueland PM, Sánchez MJ, Quirós JR, González CA, Larrañaga N, Chirlaque MD, Ardanaz E, Sieri S, Palli D, Vineis P, Tumino R, Linseisen J, Kaaks R, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Khaw KT, Bingham S, Hallmans G, Riboli E, Stattin P, Key TJ. Circulating concentrations of folate and vitamin B12 in relation to prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition study. Cancer Epidemiol Biomarkers Prev. 2008. 17:279–285.

32. Kim WJ, Chung JI, Hong JH, Kim CS, Jung Sl, Yoon DK. Epidemiological Study for Urologic Cancer in Korea (1998~2002). Korean J Urol. 2004. 1081–1088.

33. Milano L. Mediterranean diet, micronutrients and prostate carcinoma: a rational approach to primary prevention of prostate cancer. Arch Ital Urol Androl. 2003. 75:166–178.

34. Zu K, Giovannucci E. Smoking and aggressive prostate cancer: a review of the epidemiologic evidence. Cancer Causes Control. 2009. 06. 27. [Epub ahead of print].